Navigation Links
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Date:7/19/2012

receptors resulting in their degradation so that fewer are available on liver cells to remove LDL-C from the blood.  Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which limits their own ability to lower LDL-C.  Inhibiting the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-C.

About SAR236553/REGN727 and the Phase 2 Program

SAR236553/REGN727, created using Regeneron's VelocImmune® technology, is a fully human monoclonal antibody directed against PCSK9, administered via subcutaneous injection.  By inhibiting PCSK9, a determinant of circulating LDL-C levels in the blood, SAR236553/REGN727 increases the number of free LDL receptors which can clear circulating LDL-C from the bloodstream.

SAR236553/REGN727 has been studied in three Phase 2 clinical studies: two in patients with primary hypercholesterolemia and one in patients with heterozygous familial hypercholesterolemia (heFH).  In the primary hypercholesterolemia trials treatment with different dose regimens of SAR236553/REGN727 on top of statin therapy significantly reduced LDL-C from baseline by 40% to 72% over the 8 or 12-week treatment period.  A third Phase 2 study was in patients with heFH whose LDL-C levels remained elevated despite statin therapy with or without ezetimibe.  Across the four tested doses of SAR236553/REGN727 administered for up to 12 weeks, patients achieved a mean reduction in LDL-C from baseline of 28% to 68%.  In the Phase 2 program, injection site reactions were the most common adverse events with SAR236553/REGN727.  Rare cases of hypersensitivity reaction were also reported.  There were five serious adverse events (SAE) in the active treatment arms (1.8%, 5/275) and two SAEs in the placebo groups (2.6%, 2/77).

About the Phase 3 SAR236553/REGN727 Program

The Phase 3 ODYSSEY program will include over ten cli
'/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
2. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
9. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
11. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:9/2/2015)... 02, 2015 ... announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. ... besides fluorescence in situ hybridization (FISH), comparative ... cytogenetics includes application of nanobiotechnology, microarrays, real-time ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... NATICK, Mass. and WASHINGTON, Oct. 21 Boston,Scientific ... from an analysis,of nearly 7,000 patients from its ... the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting,Coronary Stent ... continued low incidences of adverse events and repeat,revascularization ...
... Oct. 20 BioSpecifics,Technologies Corp. (Pink Sheets: BSTC) today ... of the company and it,s product,pipeline at the 9th ... The presentation will take place on Wednesday November 7, ... in Holmes I. About BioSpecifics Technologies Corp ...
... Keynote Luncheon Address by James Cornelius, CEO of ... Paramount Acquisition Corp.,(OTC Bulletin Board: PMQC, PMQCU, PMQCW) ... care pharmacy based in Long Beach, New,York, will ... is being held on Tuesday, October 23 in ...
Cached Biology Technology:ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Chem Rx to Present at the Paramount BioSciences Healthcare Conference 2Chem Rx to Present at the Paramount BioSciences Healthcare Conference 3Chem Rx to Present at the Paramount BioSciences Healthcare Conference 4
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
Breaking Biology News(10 mins):Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... PITTSBURGHRegenerative medicine researchers at the University of Pittsburgh ... the National Institutes of Health (NIH) to explore new ... organs. A $2.9 million, five-year Transformative R01 (T-R01) ... in Pitt,s School of Medicine and a researcher in ...
... of Ridgeland, Mississippi, a graduate student in biological sciences ... of Health (NIH) Graduate Research Fellowship for her study ... Virus, a mosquito-borne disease that can cause seizures, coma, ... Harris, a wildlife veterinarian, is pursuing her doctoral degree. ...
... 23, 2009Using clever chemistry, a Scripps Research team has ... stops the progression of the devastating disease Friedreich,s ataxia ... The findings, developed in collaboration with scientists from Repligen ... toward human clinical trials, which will be a welcome ...
Cached Biology News:Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine 2Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine 3NIH fellowship recipient to study disease ecology 2Mechanism for potential Friedreich's ataxia drug uncovered 2Mechanism for potential Friedreich's ataxia drug uncovered 3